Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kirschfink

Showing results (11-20 of 101) with videos related to

Pageof 11
Sort By:
Expert Opinion on Pharmacotherapy|October 5, 2001
C1-inhibitor: an anti-inflammatory reagent with therapeutic potentialM Kirschfink, T E Mollnes
Experimental and Clinical Immunogenetics|January 1, 1995
Complement and IgG subclasses in agammaglobulinemic patientsA S Grumach, M Kirschfink
Vox Sanguinis|January 1, 1990
Neolacto (type-2 chain)-sialoautoantigens recognized by human cold agglutininsD Roelcke, U Hengge, M Kirschfink
Infusionstherapie Und Transfusionsmedizin|December 1, 1994
Activation of complement by cold agglutininsM Kirschfink, K Knoblauch, D Roelcke
Infusionstherapie Und Transfusionsmedizin|December 1, 1994
Red cell destruction in cold agglutinin diseaseG Zilow, M Kirschfink, D Roelcke
Experimental and Clinical Immunogenetics|November 27, 1999
Modulation of C5a-mediated effector functions of human polymorphonuclear leukocytes by tumor necrosis factor alpha and granulocyte macrophage colony-stimulating factorR Binder, A Kress, M Kirschfink
Vox Sanguinis|January 1, 1992
Complement activation by cold agglutininsM Kirschfink, H Fritze, D Roelcke
Circulatory Shock|July 1, 1993
Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfacesM Kirschfink, B Kovacs, K Mottaghy
Transplantation|December 15, 1996
Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejectionB Heckl-Ostreicher, A Wosnik, M Kirschfink
Clinical and Experimental Immunology|December 1, 1995
Functional activity of the membrane-associated complement inhibitor CD59 in a pig-to-human in vitro model for hyperacute xenograft rejectionB Heckl-Ostreicher, R Binder, M Kirschfink
Pageof 11

Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
Expert Opinion on Pharmacotherapy|October 5, 2001
C1-inhibitor: an anti-inflammatory reagent with therapeutic potentialM Kirschfink, T E Mollnes
Experimental and Clinical Immunogenetics|January 1, 1995
Complement and IgG subclasses in agammaglobulinemic patientsA S Grumach, M Kirschfink
Vox Sanguinis|January 1, 1990
Neolacto (type-2 chain)-sialoautoantigens recognized by human cold agglutininsD Roelcke, U Hengge, M Kirschfink
Infusionstherapie Und Transfusionsmedizin|December 1, 1994
Activation of complement by cold agglutininsM Kirschfink, K Knoblauch, D Roelcke
Infusionstherapie Und Transfusionsmedizin|December 1, 1994
Red cell destruction in cold agglutinin diseaseG Zilow, M Kirschfink, D Roelcke
Experimental and Clinical Immunogenetics|November 27, 1999
Modulation of C5a-mediated effector functions of human polymorphonuclear leukocytes by tumor necrosis factor alpha and granulocyte macrophage colony-stimulating factorR Binder, A Kress, M Kirschfink
Vox Sanguinis|January 1, 1992
Complement activation by cold agglutininsM Kirschfink, H Fritze, D Roelcke
Circulatory Shock|July 1, 1993
Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfacesM Kirschfink, B Kovacs, K Mottaghy
Transplantation|December 15, 1996
Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejectionB Heckl-Ostreicher, A Wosnik, M Kirschfink
Clinical and Experimental Immunology|December 1, 1995
Functional activity of the membrane-associated complement inhibitor CD59 in a pig-to-human in vitro model for hyperacute xenograft rejectionB Heckl-Ostreicher, R Binder, M Kirschfink
Pageof 11